Start / PharmaTalkRadio / Clinical update on amg 420 an anti bcma bite

PharmaTalkRadio

Clinical update on AMG 420, an anti-BCMA BiTE®

23 min • 1 november 2019

In this talk, recorded at the 5th annual IO360° Summit, Dr Alex Minella, Amgen, provides a clinical update on AMG 420, an anti-BCMA BiTE® This talk addresses the: Summary of IND enabling preclinical studiesFirst-in-human trial designFirst-in-human trial data (safety, efficacy) Save the date for the 6th annual Immuno-Oncology 360° Summit on February 26-28, 2020 at the Crowne Plaza Times Square in New York City. Learn more at www.io360summit.com

Senaste avsnitt

Stanford's Dr Crystal Mackall on the Evolution of and Future Directions in Cell Therapy

14 augusti | 29 min

De-Risking Clinical Operations by Taking a Scaffolding Approach to Outsourcing

12 augusti | 28 min

Balancing Between Concentration and Volume when Developing Patient-Centric Biologics

12 augusti | 28 min

Directors' Talk DPHARM 2025 - AI Sessions; Part III

25 juli | 6 min

Innovations in Manufacturing to Make CAR-T More Accessible and Affordable

25 juli | 20 min

Podcastbild

00:00 -00:00

Podcastbild

00:00 -00:00